Sotagliflozin is a dual SGLT1 and 2 inhibitor, and from the currently available evidence (SCORED and SOLOIST trial), the compound is likely at least as effective as the more selective SGLT2is in preventing heart failure (HF) in patients with T2DM and CKD as well as in reducing cardiovascular mortality and hospitalization for HF in patients with T2DM and HF with reduced or preserved ejection fraction (HFrEF, HFpEF) (Bhatt, Szarek, Pitt, et al., 2021; Bhatt, Szarek, Steg, et al., 2021). This evidence concerns the gene SLC5A1 and type 2 diabetes mellitus.